AI Article Synopsis

  • - Lysosomal storage disorders (LSD) are genetic metabolic conditions caused by issues with lysosomes, affecting roughly 1 in 5000 births, with Fabry and Gaucher diseases being the most prevalent
  • - These disorders primarily result from enzyme deficiencies, leading to the buildup of undegraded materials in cells, which can disrupt normal cellular function and cause toxicity or inflammation
  • - There are approved treatment options for Fabry and Gaucher diseases, including enzyme replacement therapy, chaperone therapy, and substrate reduction therapy.

Article Abstract

Lysosomal storage disorders (LSD) are a heterogenous group of inborn errors of metabolism due to lysosomal malfunction. LSDs affect 1 in 5000 live births, albeit every LSD itself has a low incidence. The most common LSDs are Fabry disease and Gaucher disease. The underlying cause mainly is an enzyme deficiency but may also be due to defects in transport or activation proteins, which result in progressive intra- and extra-lysosomal accumulation of undegraded storage material. The lysosomes play a key role in degradation and cellular recycling of macromolecules. Besides disturbance of cellular function, substrate accumulation may result in secondary toxic and/or inflammatory processes. For treatment of Fabry and Gaucher disease, several therapeutic approaches are approved including enzyme replacement therapy, chaperon therapy for Fabry disease and substrate reduction therapy for Gaucher disease.

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-2295-1592DOI Listing

Publication Analysis

Top Keywords

fabry disease
12
gaucher disease
12
storage disorders
8
disease gaucher
8
disease
6
[lysosomal storage
4
fabry
4
disorders fabry
4
gaucher
4
gaucher disease]
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!